I learned that 136 million people—about one in three Americans—have diabetes or prediabetes. Many are unaware.

The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s FY2027 earnings at $2.77 EPS and FY2028 earnings at $3.14 EPS.

Revenue growth and solid market position highlight DexCom's operational strengths. Investments in R&D and international expansion reflect strategic opportunities. Patent litigation and market ...

Revenue growth and solid market position highlight DexCom's operational strengths. Investments in R&D and international expansion reflect strategic opportunities. Patent litigation and market ...

DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents.

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

On Friday, Bernstein SocGen Group adjusted its stock price target for DexCom (NASDAQ: DXCM), a medical device company specializing in glucose monitoring systems. The new price target is set at $86 ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...

The U.S. spends $413 billion dollars each year on diabetes-related care, meaning that diabetic patients now account for one of every four healthcare dollars spent in the country. The first step in ...

Management maintained its full-year guidance for $4 billion to $4.05 billion in revenue. DexCom experienced slower growth and profitability challenges, but still met management's expectations for ...